TSE:4536
TSE:4536Pharmaceuticals

MHRA Approval of Ryjunea® Could Be a Game Changer for Santen Pharmaceutical (TSE:4536)

In the past week, Santen Pharmaceutical announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) approved Ryjunea® (low-dose atropine 0.1 mg/ml) as the first licensed treatment to slow the progression of myopia in children, following earlier European Commission approval and launches in Europe. This milestone offers Santen a new opportunity to address the rising prevalence of childhood myopia in the UK and further strengthens its international presence in paediatric...
TSE:9684
TSE:9684Entertainment

Square Enix (TSE:9684) Considers Extraordinary Loss Amid Forecast Revision Is Its Turnaround Strategy at a Crossroads?

Square Enix Holdings announced that its board met on November 6, 2025, to consider recording an extraordinary loss for the six-month period ended September 30, 2025, and to revise its consolidated financial forecast for the fiscal year ending March 31, 2026. This disclosure signals ongoing financial uncertainties for the company, even as it continues to launch high-profile titles such as the recent DRAGON QUEST I & II HD-2D Remake. We’ll explore how the anticipated extraordinary loss and the...
TSE:8113
TSE:8113Household Products

Unicharm (TSE:8113): Assessing Valuation After 9-Month Profit Rises Despite Falling Sales

Unicharm (TSE:8113) just released its financial results for the first nine months of 2025, reporting a 4% decline in sales and lower core operating income. The company still managed a modest rise in profit to shareholders. See our latest analysis for Unicharm. Unicharm’s share price has staged a modest rebound over the past week, rising nearly 5 percent, following its latest earnings update. However, the picture remains tough for long-term shareholders. The one-year total shareholder return...